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In contrast to expectations in the past that tumor starvation or unselective inhibition of pro-
teolytic activity would cure cancer, there is accumulating evidence that microenvironmental
stress, such as hypoxia or broad-spectrum inhibition of metalloproteinases can promote
metastasis. In fact, malignant tumor cells, due to their genetic and epigenetic instability,
are predisposed to react to stress by adaptation and, if the stress persists, by escape and
formation of metastasis. Recent recognition of the concepts of dynamic evolution as well
as population and systems biology is extremely helpful to understand the disappointments
of clinical trials with new drugs and may lead to paradigm-shifts in therapy strategies. This
must be complemented by an increased understanding of molecular mechanism involved
in stress response. Here, we review new roles of Hypoxia-inducible factor-1 (HIF-1), one
transcription factor regulating stress response-related gene expression: HIF-1 is crucial for
invasion and metastasis, independent from its pro-survival function. In addition, HIF-1 medi-
ates pro-metastatic microenvironmental changes of the proteolytic balance as triggered by
high systemic levels of tissue inhibitor of metalloproteinases-1 (TIMP-1), typical for many
aggressive cancers, and regulates the metabolic switch to glycolysis, notably via activation
of the microRNA miR-210.There is preliminary evidence thatTIMP-1 also induces miR-210.
Such positive-regulatory co-operation of HIF-1α, miR-210, and TIMP-1, all described to cor-
relate with bad prognosis of cancer patients, opens new perspectives of gaining insight
into molecular mechanisms of metastasis-inducing evasion of tumor cells from stress.
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INTRODUCTION
Late stage cancer with occurrence of metastasis is the greatest and
most challenging problem for research aimed at the development
of new therapeutic concepts and agents against malignant tumors.
In fact, most cancer patients die of metastasis and not of the pri-
mary tumor (Sporn, 1996). Current therapies are genotoxic-based
DNA-damaging agents and cell cycle inhibitors and show some
efficacy in early stages of cancer only (Yamaguchi and Perkins,
2012). However, in the cell population of a progressing tumor,
these therapies often select for clones which, due to their genetic
and epigenetic instability, accumulate mutations which abrogate
checkpoint functions and apoptosis-inducing programs (Yam-
aguchi and Perkins, 2012). This is the major obstacle for complete
eradication of most disseminated cancers (Gatenby, 2009).
As an alternative, more recent therapy strategies were based
on the increased knowledge of the specific molecular biology of
tumor cells.
Two prominent examples are the anti-angiogenic and anti-
proteolytic therapy approaches which aimed at depriving the
tumor cells from the line of supply of oxygen and nutrients or tools
needed to invade the surrounding tissue, respectively. Promising
target proteins were the vascular endothelial growth factor (VEGF)
as a crucial promoter of new vessel formation during angiogene-
sis (Ferrara, 2002) as well as matrix metalloproteinases (MMPs) as
important enzymes with the ability to degrade virtually all compo-
nents of the extracellular matrix (Egeblad and Werb, 2002; Overall
and López-Otin, 2002). These approaches initially were found to
be very effective in pre-clinical settings as they led to marked inhi-
bition or even shrinkage of tumors (Zucker et al., 2000; Ferrara
et al., 2004). However, application of the respective inhibitors in
clinical settings provided either disappointing results in the case
of anti-angiogenic therapies (Cai et al., 2011) or even failure of
clinical trials in the case of MMP inhibition (Zucker et al., 2000).
Indeed, it already became evident in pre-clinical experiments that
inefficacy or even detrimental effects of these therapy approaches
can arise, especially in the context of late stage cancer with metas-
tasis. While primary tumors may be inhibited by anti-angiogenic
(Casanovas et al., 2005; Ebos et al., 2009; Pàez-Ribes et al., 2009)
or anti-proteolytic (Della Porta et al., 1999) therapies, both dras-
tically promoted tumor cell invasion and metastasis (Della Porta
et al., 1999; Krüger et al., 2001; Casanovas et al., 2005; Ebos et al.,
2009). Notable examples are the induction of liver metastasis by
the hydroxamate-like synthetic inhibitor of matrix metallopro-
teases batimastat (Krüger et al., 2001) as well as findings that
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VEGFR/PDGFR kinase inhibitors or VEGFR-specific antibodies
increase multi-organ metastasis (Ebos et al., 2009) or metastasis
to the liver and lymph nodes, respectively (Pàez-Ribes et al., 2009).
The main explanation of these “surprises” relies on the too long
ignored appreciation that tumors represent an eco-system of het-
erogeneous tumor and host cell populations, where mechanisms
of evolutionary dynamics and population biology apply, leading to
the conclusion that over-simplistic interference will yield unfore-
seen and even detrimental effects (Gatenby, 2009). In addition, it
is necessary to more carefully analyze the complex interdependen-
cies of targeted gene products including the activity and expression
of connected proteins and its effect on signal transduction and cell
behavior, in other words the systems biology of specific therapeutic
interference (Krüger, 2009; Krüger et al., 2010; Sela-Passwell et al.,
2011). With such mind-set it was possible to solve the paradox why
elevated systemic levels of tissue inhibitor of metalloproteinases-
1 (TIMP-1), i.e., correlate with bad prognosis of many cancers
(Zucker et al., 2000). There is data suggesting that broad-spectrum
inhibition of MMPs by TIMP-1 interferes with the negative regu-
lation of the MET tyrosine kinase by blocking the MET-shedding
activity of ADAM-10 (Kopitz et al., 2007). MET activity is a key
promoter of the invasive growth program in tumor cells (Boccac-
cio and Comoglio, 2006). In addition, broad-spectrum inhibition
of MMPs leads to an evasive shift of proteolytic activity from the
inhibited MMPs toward serine proteases such as the urokinase-
type plasminogen activator (uPA) in the microenvironment,which
was associated with a drastic promotion of tumor cells to metas-
tasize (Kopitz et al., 2007). Such complexities and evolutionary
adaptations of tumor cells or, as in the above case of the tumor
microenvironment, are extremely relevant not only for therapeu-
tic inhibition of MMPs but for all attempts to inhibit proteases
as “obvious” tools for tumor cell invasion and metastasis (Krüger
et al., 2010).
Such Darwinian selection of tumor cells with a more aggressive
phenotype can also be the cause of problems with anti-angiogenic
therapy (Gatenby and Gillies, 2004; Michieli, 2009). Inhibition of
angiogenesis leads to hypoxia which was initially thought to lead to
suffocation of tumor cells and subsequent total elimination of the
tumor (Hanahan and Folkman, 1996; Dang and Semenza, 1999).
However, malignant tumors meet the hypoxic challenge not only
by induction of angiogenesis. Instead, in fast-growing neoplasias
hypoxia selects for malignant tumor cells which are adapted to
hypoxia by using a gene expression program allowing a meta-
bolic switch from dependence on oxygen for energy generation to
energy production under anaerobic conditions by glycolysis only
(Gatenby and Gillies, 2004). In fact, malignant tumor cells are even
able to leave the site if unfavorable conditions persist by initiat-
ing an invasive growth program (Pennacchietti et al., 2003). This
program is highly dependent on signaling of the MET tyrosine
kinase receptor (Pennacchietti et al., 2003) and ultimately leads to
metastasis, the main cause of death for cancer patients.
The ability of tumor cells to respond to stress by inducing angio-
genesis, performing glycolysis, and initiating the invasive growth
program has to be maintained throughout the steps of the metasta-
tic cascade (Gatenby and Gillies, 2004). Hypoxia-inducible factor-
1 (HIF-1) is a transcription factor which seems to be crucial for all
the above-mentioned stress responses of malignant tumor cells.
In this review we propose a molecular mechanism from avail-
able data which explains how metastasis formation can be driven
by an increase in stress on tumor cells by anti-angiogenic and anti-
proteolytic agents. We summarize evidence for and propose a new
context between one of the most central regulators of the prote-
olytic network, TIMP-1, the major regulator of tumor cell stress
response, HIF-1, and its main downstream microRNA (miRNA)
effector, miR-210.
HIF-1α REGULATES RESPONSE OF TUMOR CELLS TO STRESS
Competition with the surrounding tissue for nutrients, oxygen,
and space disturbs the proteolytic balance and forces tumor cells
to adapt, escape, or undergo apoptosis (Figure 1). Cell fate, i.e.,
whether a tumor cell succumbs to the stress by apoptosis (death),
adapts by ensuring survival at the site (stay) or leaves in the search
of better conditions (escape) is determined by HIF-1 dependent
intracellular pathways (Figure 1). Under normoxic conditions
HIF-1α, one of two subunits of HIF-1, is hydroxylated by iron- and
oxygen-dependent prolyl-hydroxylases (Lando et al., 2002; Kaelin
and Ratcliffe, 2008), modified by the E3 ubiquitin ligase von Hip-
pel Lindau (Jaakkola et al., 2001), and subsequently degraded in
the proteasome. A lack of oxygen renders the prolyl-hydoxylases
inactive so that HIF-1α can associate with constitutively expressed
HIF-1β and form the heterodimer HIF-1 (Majmundar et al., 2010).
HIF-1 translocates to the nucleus, binds to hypoxia-response ele-
ments (HREs), and initiates transcription of target genes which
allow adaptation to stress (Wenger et al., 2005).
HIF-1 can also be induced by hypoxia-independent factors
(Wenger et al., 2005), such as inflammatory cytokines like IFN-γ
and IL-4 (Majmundar et al., 2010) as well as NF-κB (Wilczyn-
ski et al., 2011). HIF-1α mRNA expression and protein stabil-
ity are further upregulated by mTORC1 (Bernardi et al., 2006)
and the PI3K pathway (Mottet et al., 2003), which can initiate a
HIF-1-mediated response independent of hypoxic stress.
Recently, high level of metalloproteinase inhibitor TIMP-1 in
the tumor microenvironment was discovered as a new inducer of
HIF-1 in a liver metastasis model (Schelter et al., 2011b). Based
on this observation, the induction of HIF-1α gene expression by
TIMP-1 was further confirmed in vitro: Exposure of a lymphoma
tumor cell line to recombinant TIMP-1 led to an increase in HIF-
1α mRNA level, protein and the HIF-1α downstream target CA-9
(Schelter et al., 2011b). This observation represents a new connec-
tion between the major regulator of stress response in tumor cells,
HIF-1, and TIMP-1, a central player of the proteolytic network.
TIMP-1 determines tissue homeostasis (Krüger et al., 2010) and
can, if systemically elevated, promote metastasis (Kopitz et al.,
2007). As metastasis accounts for 90% of solid tumor depen-
dent deaths (Gupta and Massagué, 2006), the induction of the
metastatic potential of tumor cells by TIMP-1 and HIF-1 must be
considered crucial for successful treatment of malignant tumors.
REGULATION OF TUMOR CELL INVASION BY HIF-1
In addition to its critical role in tumor cell survival during hypoxic
conditions in metastasis (Gatenby and Gillies, 2004), HIF-1 also
directly promotes tumor cell malignancy by induction of an
aggressive phenotype (Lu and Kang, 2010). HIF-1 leads to an
upregulation of glycolysis while at the same time suppressing
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FIGURE 1 |The proposed model of molecular mechanisms regulating
the three choices of tumor cells under stress. Microenvironmental
factors regulate the activity of HIF-1α. In addition to normoxia or hypoxia,
changes of the proteolytic network can also determine the response of
the tumor cell. While normoxia and proteolytic balance favor proliferation
(right panel), which reflects the adaption of the tumor cell in situ, hypoxia
or alterations in the proteolytic network promote the induction of
pro-evasive mechanisms (left panel). Respiration is impaired upon HIF-1α
stabilization not only by hypoxia but also in the case of proteolytic
imbalance imposed by high TIMP-1 levels or similar environmental stress.
It leads to upregulation of miR-210 which directly inhibits expression of the
subunit D of the succinate dehydrogenase complex (SDHD) and
simultaneously induces cell cycle arrest by inhibition of E2F3. Thus, the
tumor cell switches to the evasive metastatic phenotype for which
adaptation to hypoxia by their potential of executing anaerobic glycolysis is
a pre-requisite.
oxidative phosphorylation. Two consequences result from this
metabolic adaptation: firstly, oxygen is no longer a limiting co-
factor necessary for cellular energy supply. Secondly, lactate gen-
erated at the same time in large amounts can serve as a precursor
for many metabolic intermediates needed for cell growth (Gatenby
and Gillies, 2004). Secreted lactate can also be used by surrounding
oxygenated tumor cells imported by the transporter MCT1, which
in this context may be a possible therapeutic target (Sonveaux
et al., 2008; Le Floch et al., 2011). Independence from oxygen and
efficient lactate transport resourcefully exploit the available energy
sources in the tumor (Sonveaux et al., 2008).
In order to balance the much less effective aerobic glycolysis,
glucose uptake is increased by upregulation of glucose transporters
like GLUT-1 by HIF-1 (Chen et al., 2001). In addition, a variety of
pro-angiogenic factors including the VEGF (Forsythe et al., 1996)
and PDGF (Bos et al., 2005) are upregulated by HIF-1 to ensure
a sufficient supply of glucose and to escape the lack of oxygen
resulting from the diffusion limit in solid fast-growing tumors.
Persistent lack of oxygen can ultimately lead to the selection of
tumor cells which exhibit a more aggressive and invasive pheno-
type and allows escape from unfavorable conditions (Gatenby and
Gillies, 2004). HIF-1 promotes metastasis by initiating epithelial-
to-mesenchymal transition by the induction of the transcription
factors Snail (Mak et al., 2010) and Twist (Yang et al., 2008), which
in turn lead to a repression of E-Cadherin. Additionally, HIF-1
induces the expression of MET tyrosine kinase receptor (Pen-
nacchietti et al., 2003) via HRE in the MET promoter region
(Pennacchietti et al., 2003). MET-signaling in turn leads to an
increase in cell motility and invasiveness which furnishes metas-
tasis (Pennacchietti et al., 2003). Furthermore, HIF-1 promotes
the expression of proteases enabling tumor cells to break through
physical borders (Krishnamachary et al., 2003; Schelter et al.,
2010).
The above-mentioned in vitro observations left it open,whether
HIF-1α regulates tumor cell invasiveness directly in vivo and what
molecular mechanisms determine direct pro-invasive functions
of HIF-1 signaling (Bertout et al., 2008; Ruan et al., 2009). Until
recently, it was hard to clarify this topic as the survival of tumor
cells under microenvironmental stress usually depends on HIF-1
signaling (Semenza, 2003). Indeed, it could not be excluded that
reduced metastasis upon HIF-1α depletion was simply a reflection
of decreased survival (Schelter et al., 2010). Recently, this distinc-
tion was achieved using a hypoxia-tolerant tumor cell line, which
does not rely on HIF-1 signaling for survival. It was shown that
HIF-1 directly controls pro-invasive and pro-metastatic features of
tumor cells independent of its promotion of cell viability (Schelter
et al., 2010). Further, it was shown that HIF-1 plays a central role
in the efficacy of metastasis formation and organ colonization
by induction of MMP-9, one of the major gelatinases expressed
by invasive tumor cells (Schelter et al., 2010). This separation of
survival-dependent and independent HIF-1 effects allows differ-
entiation between tumorigenic and metastasis-promoting effects
of HIF-1, leading to a deeper insight into metastatic processes and
stress response.
HIF-INDUCED miR-210 AND THE SWITCH TO ESCAPE MODE
Recently, an additional level of HIF-dependent transcriptional reg-
ulation was elucidated,which involved HIF-induced up-regulation
of miRNA (Kulshreshtha et al., 2007). MiRNAs function as compo-
nents of ribonucleoprotein complexes referred as miRNA-induced
silencing complexes (miRISCs). They primarily regulate gene
expression through inhibition of RNA translation by binding to
www.frontiersin.org July 2012 | Volume 3 | Article 134 | 3
Cui et al. Pro-metastatic co-operation of TIMP-1, Hif-1α, miR-210
their target gene’s 3′ UTR. They also induce mRNA decay, resulting
in the down-regulation of target mRNAs (Esquela-Kerscher and
Slack, 2006; Ortholan et al., 2009; Fabian et al., 2010).
Upon hypoxia, microRNA miR-210 is induced by HIF-1 (Kul-
shreshtha et al., 2007). While a number of miRNAs are associated
with stress response in tumor cells, miR-210 is the only “hypox-
amir” which is most significantly upregulated in a number of
cancers (Chan and Loscalzo, 2010). MiR-210 mediates a number
of known HIF-1 downstream effects, most importantly the HIF-1
dependent suppression of oxidative phosphorylation (Chan et al.,
2011).
Mechanistical insight into how HIF-1 inhibits mitochondrial
respiration could be provided by studying the role of miR-210
in HIF-1 signal transduction: miR-210 regulates ISCU1/2 expres-
sion, a protein associated with iron metabolism and leads to its
repression upon stress (Chan et al., 2009). In addition, miR-210
was shown to target Succinate Dehydrogenase Subunit D (Puis-
ségur et al., 2011), a component of the mitochondrial complex II.
This provides evidence that miR-210 mediates the functional loss
of the respiratory chain, the metabolic switch induced in tumor
cells upon hypoxic stress (Gatenby and Gillies, 2004).
Moreover, miR-210 is also involved in cell cycle by regulation of
the E2F3 transcription factor: miR-210 mediates the suppression
of E2F3 protein expression and might attenuate cell proliferation
(Giannakakis et al., 2008; Puisségur et al., 2011).
In addition, a recent study showed that not only HIF-1 induces
miR-210 transcription but that vice versa miR-210 stabilizes HIF-
1α (Puisségur et al., 2011). The inhibition of miR-210 shortens
the HIF-1 activity which indicates a positive auto-regulatory loop
based on the suppression of the afore-mentioned Succinate Dehy-
drogenase Subunit D (SDHD) by miR-210 (Puisségur et al., 2011).
Low level of Succinate Dehydrogenase subsequently leads to an
accumulation of succinate which in turn inhibits HIF-1α prolyl-
hydroxylases (Selak et al., 2005). An inhibition of HIF-1α regu-
lating enzymes delays the degradation of HIF-1α and stabilizes
HIF-1 (Puisségur et al., 2011). Thus, HIF-1, miR-210, and SDHD
are not only connected by linear transcriptional regulation but are
indeed involved in an auto-regulatory loop on protein level which
prolongs HIF-1 activity and signaling.
In conclusion, the effects of miR-210 on proliferation and
metabolism together with the stabilization of HIF-1 lead to an
accentuation of tumor cell stress response (Figure 1). Malignant
cells are selected for their ability to evade stress present in their
microenvironment. They are able to do so as they adopt a more
aggressive phenotype and increase their metastatic potential as
suggested by a very recent study (Ying et al., 2011).
In addition to the effect of stress-induced expression of miR-
210 on tumor cells, one could speculate that miR-210 is involved
in the manipulation of pre-malignant tissue and modulation of
the microenvironment at metastatic sites. To successfully colonize
potential target tissue, tumor cells depend upon stromal and vas-
cular cells (Gupta and Massagué, 2006). Hypoxic regions within
metastases and high acidity in the tumor cell microenvironment
stimulate HIF-1 dependent stress response not only in tumor cells
but also in their direct microenvironment (Dayan et al., 2008).
Induction of HIF-1 signaling and the effects of miR-210 might
therefore not only promote an aggressive phenotype in tumor cells
but also indirectly support metastasis by modulation of neighbor-
ing cells. This speculation is supported by the observation that
forced expression of miR-210 in endothelial cells stimulated the
formation of capillary-like structures and VEGF response and thus
might promote angiogenesis upon hypoxia (Fasanaro et al., 2008).
It is also possible that not only hypoxia but also hypoxia-
independent induction of HIF-1, e.g., by TIMP-1 (Schelter et al.,
2011b), could stimulate miR-210 transcription, as we have pre-
liminary evidence that exogenous TIMP-1 can lead to miR-210
upregulation in mouse livers.
TIMP-1, A POSSIBLE REGULATOR OF PRO-EVASIVE STRESS
RESPONSE?
TIMP-1 stands out as a soluble factor which does not only mod-
ulate the extracellular matrix by regulation of MMP-activity but
as an inducer of HIF-1α, it also decides over cell fate by guiding
tumor cells toward an invasive phenotype. The two mechanisms by
which TIMP-1 interferes with the metastatic potential of a tumor
cell can be demonstrated by the example of the HGF receptor MET.
First, MET is stabilized on protein level by high TIMP-1 levels via
the inhibitory effects of TIMP-1: as an inhibitor of ADAM-10,
it prevents shedding of MET, leading to higher cell surface lev-
els. This enables both the more effective signaling of HGF as well
as HGF independent dimerization of MET which also results in
increased signal transduction (Kopitz et al., 2007). Second, on a
transcriptional level, TIMP-1 might activate HIF-1 which in turn
upregulates the gene expression of MET by binding to the MET
promoter (Pennacchietti et al., 2003).
A clue of the role of TIMP-1 in metastatic progression was
recently shown utilizing a TIMP-1 knock down in tumor cells
which significantly decreased tumor cell invasiveness and reduced
the number of metastasis (Schelter et al., 2011a). Taken together
with the newly discovered connection between TIMP-1 and HIF-
1α expression, TIMP-1 evolves as an outstanding cutting point
between stress response and the proteolytic network.
CONCLUSION
Until recently TIMP-1 and HIF-1α (and in consequence miR-210)
were seemingly totally un-related factors whose elevation is asso-
ciated with bad prognosis for cancer patients (Zucker et al., 2000;
Chan and Loscalzo, 2010; Wilczynski et al., 2011). In this review,
we propose a functional pro-metastatic co-operation of these fac-
tors that link microenvironmental conditions to stress response
involving the emerging field of gene regulation by miRNAs. Recent
attempts to understand the complexity of system-wide cell signal-
ing networks led to a deeper understanding of how self-contained
networks can engage in crosstalk and contribute to cancer progres-
sion. The link between the proteolytic network and stress-related
signaling by the natural broad-spectrum inhibitor TIMP-1 is one
example of how interference with one network impacts on cell
fate-decisions mediated by another pathway.
There is now increasing evidence that current experimental
therapy approaches to eradicate the primary tumor may indeed
lead to increased tumor cell aggressiveness. This aggressiveness,
in turn, seems to be a natural adaptation strategy to environ-
mental pressure known from all aspects of evolutionary selection.
Future therapeutic targets should consider the context of both the
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flexibility and interplay of different balanced networks and the
ability of tumor cells to adapt to environmental stress. Here, we
evaluated recent evidence, of how changes in tissue homeosta-
sis, e.g., by alteration in the proteolytic network can impact on
metastasis by HIF-1 dependent increase in tumor cell invasiveness
and aggressiveness. This link is provided by TIMP-1, which can
elicit HIF-1-induced stress response (Schelter et al., 2010, 2011b)
and lead to increased metastasis in addition to the pro-metastatic
effects of TIMP-1 related to its inhibitory properties (Kopitz et al.,
2007; Schelter et al., 2011a). Indeed, paradigm-shifts in the treat-
ment of cancer (Gatenby, 2009), which include a more holistic
appreciation of the underlying mechanisms seem to be necessary
to overcome current problems in the field. Combinational therapy
(Pennacchietti et al., 2003; Cunningham et al., 2011) or moderate
treatments, aiming on containing the tumor instead of curing it
(Gatenby, 2009), might overcome adaptation strategies of tumor
cells. Anti-angiogenic reagents paired with inhibitors of MET-
signaling are currently under test after the suggestion in 2003 (Pen-
nacchietti et al., 2003; Michieli, 2009). Further, more knowledge on
HIF-1 pathway inhibitors, including strategies targeting miRNAs
(Medina and Slack, 2009) such as miR-210, might help to outwit
tumor cells by removing the driving force of evolutionary pressure
(Semenza, 2003; Lu and Kang, 2010; Wilczynski et al., 2011).
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